BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 31590640)

  • 1. PREPARE: protocol for a stepped wedge trial to evaluate whether a risk stratification model can reduce preterm deliveries among women with suspected or confirmed preterm pre-eclampsia.
    Dias MAB; De Oliveira L; Jeyabalan A; Payne B; Redman CW; Magee L; Poston L; Chappell L; Seed P; von Dadelszen P; Roberts JM;
    BMC Pregnancy Childbirth; 2019 Oct; 19(1):343. PubMed ID: 31590640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PREPARE: A Stepped-Wedge Cluster-Randomized Trial to Evaluate Whether Risk Stratification Can Reduce Preterm Deliveries Among Patients With Suspected or Confirmed Preterm Preeclampsia.
    De Oliveira L; Roberts JM; Jeyabalan A; Blount K; Redman CW; Poston L; Seed PT; Chappell LC; Dias MAB;
    Hypertension; 2023 Oct; 80(10):2017-2028. PubMed ID: 37431663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble fms-like tyrosine kinase-1 and placental growth factor kinetics during and after pregnancy in women with suspected or confirmed pre-eclampsia.
    Saleh L; van den Meiracker AH; Geensen R; Kaya A; Roeters van Lennep JE; Duvekot JJ; Verdonk K; Steegers EAP; Russcher H; Danser AHJ; Visser W
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):751-757. PubMed ID: 28600845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
    Duhig KE; Myers J; Seed PT; Sparkes J; Lowe J; Hunter RM; Shennan AH; Chappell LC;
    Lancet; 2019 May; 393(10183):1807-1818. PubMed ID: 30948284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARROT Ireland: Placental growth factor in Assessment of women with suspected pre-eclampsia to reduce maternal morbidity: a Stepped Wedge Cluster Randomised Control Trial Research Study Protocol.
    Hayes-Ryan D; Hemming K; Breathnach F; Cotter A; Devane D; Hunter A; McAuliffe FM; Morrison JJ; Murphy DJ; Khashan A; McElroy B; Murphy A; Dempsey E; O'Donoghue K; Kenny LC
    BMJ Open; 2019 Mar; 9(2):e023562. PubMed ID: 30826791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should angiogenic markers be included in diagnostic criteria of superimposed pre-eclampsia in women with chronic hypertension?
    Binder J; Kalafat E; Palmrich P; Pateisky P; Khalil A
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):192-201. PubMed ID: 34165863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidural therapy for the treatment of severe pre-eclampsia in non labouring women.
    Ray A; Ray S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD009540. PubMed ID: 29181841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of very preterm preeclampsia via heparin-mediated extracorporeal LDL-precipitation (H.E.L.P.) apheresis: The Freiburg preeclampsia H.E.L.P.-Apheresis study.
    Winkler K; Contini C; König B; Krumrey B; Pütz G; Zschiedrich S; Pecks U; Stavropoulou D; Prömpeler H; Kunze M; Markfeld-Erol F
    Pregnancy Hypertens; 2018 Apr; 12():136-143. PubMed ID: 29858106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
    Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
    Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
    Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
    Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placental growth fActor Repeat sampling for Reduction of adverse perinatal Outcomes in women with suspecTed pre-eclampsia: study protocol for a randomised controlled trial (PARROT-2).
    Hurrell A; Sparkes J; Duhig K; Seed PT; Myers J; Battersby C; Clark K; Green M; Hunter RM; Shennan AH; Chappell LC; Webster L
    Trials; 2022 Sep; 23(1):722. PubMed ID: 36056408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia.
    Khalil A; Maiz N; Garcia-Mandujano R; Penco JM; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Mar; 47(3):324-31. PubMed ID: 26387758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The soluble fms-like tyrosin kinase-1 (sFLT-1) to placental growth factor (PIGF) ratio as a possible indicator for the severity of preeclampsia - single institution experience.
    Müller A; Horvat V; Vulin M; Mandić S; Šerić V; Vidosavljević D
    Med Glas (Zenica); 2019 Feb; 16(1):53-59. PubMed ID: 30680983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of the sFlt-1/PlGF ratio to rule out preeclampsia requiring delivery in women with suspected disease. Is the evidence reproducible?
    Sabrià E; Lequerica-Fernández P; Ganuza PL; Ángeles EE; Escudero AI; Martínez-Morillo E; Alvárez FV
    Clin Chem Lab Med; 2018 Jan; 56(2):303-311. PubMed ID: 28841572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews.
    Shepherd E; Salam RA; Middleton P; Makrides M; McIntyre S; Badawi N; Crowther CA
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012077. PubMed ID: 28786098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis biomarkers for the prediction of severe adverse outcomes in late-preterm preeclampsia.
    Villalain C; Herraiz I; Cantero B; Quezada S; Lopez A; Simón E; Galindo A
    Pregnancy Hypertens; 2020 Jan; 19():74-80. PubMed ID: 31927324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic indicators of severe disease in late preterm pre-eclampsia to guide decision making on timing of delivery: The PEACOCK study.
    Duhig KE; Seed PT; Placzek A; Sparkes J; Hendy E; Gill C; Brockbank A; Shennan AH; Thangaratinam S; Chappell LC
    Pregnancy Hypertens; 2021 Jun; 24():90-95. PubMed ID: 33770588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis.
    Frampton GK; Jones J; Rose M; Payne L
    Health Technol Assess; 2016 Nov; 20(87):1-160. PubMed ID: 27918253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. sFlt-1/PlGF for prediction of early-onset pre-eclampsia: STEPS (Study of Early Pre-eclampsia in Spain).
    Perales A; Delgado JL; de la Calle M; García-Hernández JA; Escudero AI; Campillos JM; Sarabia MD; Laíz B; Duque M; Navarro M; Calmarza P; Hund M; Álvarez FV;
    Ultrasound Obstet Gynecol; 2017 Sep; 50(3):373-382. PubMed ID: 27883242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.